Proteostasis Therapeutics, Inc. Presents Preclinical Data on Parkinson’s Disease and Cystic Fibrosis Targets at EMBO Conference
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurodegenerative and orphan diseases, today presented data on the Company’s preclinical targets for Parkinson’s disease and cystic fibrosis at a conference hosted by the European Molecular Biology Organization (EMBO). The meeting, entitled “The Biology of Molecular Chaperones: From Molecules, Organelles and Cells to Misfolding Diseases,” is being held May 17-22 in Santa Margherita di Pula, Italy.
Help employers find you! Check out all the jobs and post your resume.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with neurodegenerative and orphan diseases, today presented data on the Company’s preclinical targets for Parkinson’s disease and cystic fibrosis at a conference hosted by the European Molecular Biology Organization (EMBO). The meeting, entitled “The Biology of Molecular Chaperones: From Molecules, Organelles and Cells to Misfolding Diseases,” is being held May 17-22 in Santa Margherita di Pula, Italy.
Help employers find you! Check out all the jobs and post your resume.